Abstract
Colony stimulating factor 1 receptor kinase (CSF1R) is a well validated molecular target for anticancer drug discovery. Herein, we report the design, synthesis, and structure-activity relationship study of 2-oxo-3,4-dihydropyrimido[4,5- d]pyrimidines as new orally bioavailable CSF1R inhibitors. One of the most promising compounds, 3bw, potently inhibits CSF1R kinase with an IC50 value of 3.0 nM, while it is less potent against structurally related epidermal growth factor receptor (EGFR) and other kinases. The kinase inhibition of 3bw was further validated by Western blotting analysis in RAW264.7 macrophages. The molecule also potently blocks macrophage infiltration, abrogates the protumorigenic influences of macrophages, and exhibits reasonable pharmacokinetic profile. Compound 3bw may serve as a new valuable lead compound for future anticancer drug discovery.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antineoplastic Agents / chemical synthesis*
-
Antineoplastic Agents / pharmacokinetics
-
Antineoplastic Agents / pharmacology*
-
Biological Availability
-
Cell Movement / drug effects
-
Drug Design
-
ErbB Receptors / chemistry
-
Macrophages / drug effects
-
Male
-
Mice
-
Models, Molecular
-
Molecular Structure
-
Neutrophil Infiltration / drug effects
-
Protein Kinase Inhibitors / chemical synthesis*
-
Protein Kinase Inhibitors / pharmacokinetics
-
Protein Kinase Inhibitors / pharmacology
-
Pyrimidines / chemical synthesis*
-
Pyrimidines / pharmacokinetics
-
Pyrimidines / pharmacology*
-
RAW 264.7 Cells
-
Rats
-
Rats, Sprague-Dawley
-
Receptors, Granulocyte-Macrophage Colony-Stimulating Factor / antagonists & inhibitors*
-
Structure-Activity Relationship
Substances
-
Antineoplastic Agents
-
CSF1R protein, human
-
Protein Kinase Inhibitors
-
Pyrimidines
-
Receptors, Granulocyte-Macrophage Colony-Stimulating Factor
-
ErbB Receptors